or
Looking to list your PhD opportunities? Log in here.
The incidence of the brittle bone disease osteogenesis imperfecta (OI) is estimated to be around 1 in 10,000 individuals. The phenotypic spectrum of OI ranges from mild to perinatal lethal and includes extra-skeletal connective tissue manifestations.
Molecular mechanisms held responsible for OI include insufficiencies or defects in the bone collagenous extracellular matrix (ECM), as well as osteoblast dysfunction caused by overload of protein degradation pathways. Intracellular alterations can include over-modification of the procollagen molecule, activation of branches of the unfolded protein response (UPR) pathway or the integrated stress response, canonical or non-canonical autophagy and cytoskeletal alterations.
Type I collagen is the major structural component of bone and its molecules are predominantly (α1)2(α2)1 heterotrimers derived from the polypeptide gene products of the COL1A1 and COL1A2 genes. The mouse ‘osteogenesis imperfecta murine (oim)’ OI model is caused by deletion of a single guanidine residue in COL1A2, causing a frameshift that alters the last 47 amino acids, and adds an additional residue to the α2 chain of type I procollagen. As the α2 chain is defective, solely homotrimeric (α1)3 type I collagen is produced in oim homozygotes that have brittle bones. However, it is not the homotrimeric type I collagen itself that causes bone fragility (Lee et al., 2022). Intriguingly we did not detect synthesis of the abnormal (pro)α2(I) chain in oim homozygotes, even when autophagy or proteosomal degradation was inhibited, despite the presence of mRNA from the oim allele in both heterozygotes and homozygotes
These findings lead to the question of whether the oim proα2(I) chain is translated and at what rate, and how it affects the rate of synthesis of the normal proα1(I) chain.
The studentship will include training for the relevant techniques required for the project which include cDNA cloning and mutagenesis, established and primary cell culture, transfection, confocal microscopy and live cell imaging. For the final objective, training will also be provided in tissue dissection for explant culture and electron microscopy.
Understanding the fundamental reasons for brittle bone disease has the potential to lead to the identification of molecular therapies to treat the condition.
The university will respond to you directly. You will have a FindAPhD account to view your sent enquiries and receive email alerts with new PhD opportunities and guidance to help you choose the right programme.
Log in to save time sending your enquiry and view previously sent enquiries
The information you submit to University of Liverpool will only be used by them or their data partners to deal with your enquiry, according to their privacy notice. For more information on how we use and store your data, please read our privacy statement.
Based on your current searches we recommend the following search filters.
Check out our other PhDs in Liverpool, United Kingdom
Start a New search with our database of over 4,000 PhDs
Based on your current search criteria we thought you might be interested in these.
Discovery of New Treatments for Parkinson’s disease
Cardiff University
Multimerisation of ELAV/Hu proteins – a key mechanism ensuring specificity for RNA recognition in health and disease
The University of Manchester
MSc by Research: Sugar ubiquitylation, a new quality control mechanism for the recognition and elimination of unbranched glycogen?
University of Dundee